MRNA—(+17%)—is the biggest gainer in the S&P 500 as I’m typing. When a cancer vaccine works in any trial, it’s pretty big news. When a cancer vaccine produces a hazard ratio for DFS as good as 0.56 (lower is better) in a phase-2b trial, it’s even bigger news.
Market Data 
Markets 
AI
